-
Mashup Score: 1Results on Novartis prostate cancer therapy could expand its use - 6 month(s) ago
Results presented Monday could expand the use of a Novartis therapy for metastatic prostate cancer.
Source: www.statnews.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 0Ribociclib regimen reduces recurrence risk in subset of patients with early breast cancer - 1 year(s) ago
The addition of ribociclib to adjuvant endocrine therapy significantly reduced the risk for disease recurrence among patients with hormone receptor-positive, HER2-negative early breast cancer, according to the agent’s manufacturer. Ribociclib (Kisqali, Novartis), a category 1 preferred CDK 4/6 inhibitor, showed consistent benefit regardless of nodal involvement among patients with stage II
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Ribociclib regimen REDUCES recurrence risk in subset of patients with early breast cancer. https://t.co/fPN50riLw5 #breastcancer #Novartis @UCLAJCCC #Ribociclib #HemOnc #OncAlert #MedEd
-
-
Mashup Score: 0Welcome to Gene Therapy Net - 2 year(s) ago
Gene Therapy Net is the web resource for patients and professionals interested in gene therapy. The objectives of Gene Therapy Net are to be the information resource for basic and clinical research in gene therapy, cell therapy, and genetic vaccines, and to serve as a network in the exchange of info…
Source: www.genetherapynet.comCategories: Future of Medicine, Latest HeadlinesTweet-
Novartis Confirms Deaths of Two Patients Treated with Gene Therapy Zolgensma. https://t.co/JQCyx0Trgo #novartis #ZOLGENSMA
-
-
Mashup Score: 1Above The Fold in Healthcare - 2 year(s) ago
The Front Page of Healthcare News on the Internet by C. Michael Gibson MD
Source: paper.liCategories: Expert Picks, Latest HeadlinesTweet-
The latest Above The Fold in Healthcare! https://t.co/DgFFXEUsje Thanks to @Reuters_Health @NEJM @NPRHealth #covid19 #novartis
-
-
Mashup Score: 1Novartis to Cut up to 8,000 Jobs World-Wide - 2 year(s) ago
The Swiss pharmaceutical giant’s job cuts, including 1,400 in Switzerland, are part of a previously disclosed restructuring plan aimed at saving some $1 billion in costs.
Source: WSJCategories: Expert Picks, Latest HeadlinesTweet-
Swiss pharmaceutical giant #Novartis said it plans to shed as many as 8,000 jobs globally, including 1,400 in Switzerland, as part of a previously disclosed restructuring plan aimed at saving some $1 billion in costs. https://t.co/9tgLuuO0me
-
-
Mashup Score: 0Lymphoma Daily - 2 year(s) ago
Content directly from sources and does not necessarily reflect my views by Jason R Westin
Source: paper.liCategories: Hem/Oncs, Latest HeadlinesTweet-
The latest Lymphoma Daily! https://t.co/QvTpCyWbm5 Thanks to @thudderwicks @mohammadali_im @PunaDave #novartis #ngs
-
-
Mashup Score: 1Novartis empowers scientists with AI to speed the discovery and development of breakthrough medicines | Transform - 2 year(s) ago
Designing new medicines typically takes years. With AI, Novartis scientists aim to make such breakthroughs in weeks, even days.
Source: TransformCategories: Healthcare Professionals, Latest HeadlinesTweet-
🥼 Scientists’ ability to predict which molecules can be transformed into medicines traditionally takes DECADES and can cost billions. With #Microsoft #AI, #Novartis may be able to shorten that process to weeks or even DAYS 💥@MSFT_Business #lifesciences https://t.co/aPnXduvrSZ https://t.co/Au5CXIYBUD
-
-
Mashup Score: 0Register - Gene Therapy for Ophthalmic Disorders 2021 - 3 year(s) ago
Register Online registration for this meeting is now open! When booking the workshop day, please select Workshop B or Workshop C. Industry Pricing Register & Pay by September, 21 to save $200 Conference + Workshop Day (Select Workshop B or C) $3,296 Conference Only $2,099 SECURE YOUR PLACE Group Discounts Available: • 10% discount –…Read more
Categories: Future of Medicine, Latest HeadlinesTweet-
Discover novel vectors and administration routes for optimal retinal delivery with 30+ world class speakers from #GenSightBiologics, #Biogen, #GyroscopeTherapeutics, #Novartis, #Horama and #REGENXBIO at the 2nd Gene Therapy for Ophthalmic Disorders https://t.co/Fx4Pzwwnfh
-
-
Mashup Score: 2Supreme Court declines to hear Sandoz's appeal for Enbrel biosimilar, upholds Amgen patent - 3 year(s) ago
The U.S. Supreme Court has denied a petition from Novartis’ Sandoz to review an earlier U.S. appeals court ruling in favor of Amgen’s etanercept against etanercept-szzs, effectively blocking the biosimilar from entering the U.S. market. In July 2020, the U.S. Court of Appeals for the Federal Circuit ruled in a 2-1 decision that the Sandoz biosimilar Erelzi (etanercept-szzs) infringed
Source: www.healio.comCategories: Latest Headlines, RheumatologyTweet-
The U.S. #SupremeCourt has denied a petition from #Novartis’ #Sandoz to review an earlier U.S. appeals court ruling in favor of #Amgen’s #etanercept against etanercept-szzs, effectively blocking the #biosimilar from entering the U.S. market https://t.co/EPsIg9hgRI
-
-
Mashup Score: 2Novartis acquires digital therapeutic using video games, 3D glasses to treat 'lazy eye' - 3 year(s) ago
Alongside the purchase of Amblyotech, the pharma company announced upcoming collaborations with major video game publisher Ubisoft and McGill University.
Source: MobiHealthNewsCategories: Healthcare Professionals, Latest HeadlinesTweet-
Our Prediction#5 for 2020: A major pharma company will make an unexpected acquisition of a medtech or wearables player ✔️ #Reality: There have been at least two that match this: #novartis https://t.co/uX3FLZjA2G and #Otsuka https://t.co/uBCk6waQwo https://t.co/LqepLa0j08
-
Results on #Novartis prostate cancer therapy could expand its use. https://t.co/UJVrJL2IeM